Sees 2026 non-GAAP operating income $1.4B-$1.5B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- Beigene, Ltd. (ONC) Q4 Earnings Cheat Sheet
- BeOne Medicines price target raised to $394 from $385 at Barclays
- Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors
- Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
- BeiGene’s BGB-24714 Solid Tumor Trial Terminated: What It Means for Oncology Investors